Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma

详细信息    查看全文

• 作者：Alicia M. Waters^* ; Laura L. Stafman^* ; Evan F. Garner^* ; Smitha Mruthyunjayappa^* ; Jerry E. Stewart^* ; Gregory K. Friedman^&dagger ; ; Jennifer M. Coleman^&Dagger ; ; James M. Markert^&Dagger ; ; G. Yancey Gillespie^&Dagger ; ; Elizabeth A. Beierle^* ; ^{elizabeth.beierle@childrensal.org" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Translational Oncology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：9
• 期：5
• 页码：419-430
• 全文大小：1509 K

文摘

Rhabdomyosarcoma (RMS), a tumor of skeletal muscle origin, is the most common sarcoma of childhood. Despite multidrug chemotherapy regimens, surgical intervention, and radiation treatment, outcomes remain poor, especially in advanced disease, and novel therapies are needed for the treatment of these aggressive malignancies. Genetically engineered oncolytic viruses, such as herpes simplex virus-1 (HSV), are currently being explored as treatments for pediatric tumors. M002, an oncolytic HSV, has both copies of the γ₁34.5 gene deleted, enabling replication in tumor cells but thwarting infection of normal, postmitotic cells. We hypothesized that M002 would infect human RMS tumor cells and lead to decreased tumor cell survival in vitro and impede tumor growth in vivo. In the current study, we demonstrated that M002 could infect, replicate in, and decrease cell survival in both embryonal (ERMS) and alveolar rhabdomyosarcoma (ARMS) cells. Additionally, M002 reduced xenograft tumor growth and increased animal survival in both ARMS and ERMS. Most importantly, we showed for the first time that repeated dosing of oncolytic virus coupled with low-dose radiation provided improved tumor response in RMS. These findings provide support for the clinical investigation of oncolytic HSV in pediatric RMS.